Greenland Mines (GRML) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Kalaris Therapeutics (KLRS) has outperformed Greenland Mines (GRML) over the past year, losing 49.0% versus a loss of 83.3%. Greenland Mines is the larger company by market cap ($69.0 million vs $56.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRML | KLRS |
|---|---|---|
| Share price | $5.17 | $2.36 |
| Market cap | $69.00M | $56.18M |
| 1-day change | -12.07% | -5.60% |
| YTD return | -64.22% | -72.04% |
| 1-year return | -83.30% | -48.97% |
| 5-year return | — | -99.54% |
| EPS (TTM) | $-9.74 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.00 | $11.88 |
| 52-week low | $2.82 | $2.35 |
| Distance from 52-week high | -86.03% | -80.13% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2027.66% | +692.80% |
| Average volume | 7.92M | 252.88K |
| Shares outstanding | 13.35M | 23.80M |
| Employees | 5 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KLRS has outperformed GRML by 34.3 percentage points over the past year.
About Greenland Mines
GRML stock →Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
GRML vs KLRS FAQ
Which is bigger, Greenland Mines or Kalaris Therapeutics?
Greenland Mines (GRML) is larger, with a market capitalization of $69.00M compared with $56.18M for Kalaris Therapeutics (KLRS).
Which stock has performed better over the past year, GRML or KLRS?
KLRS returned -48.97% over the past 12 months, compared with -83.30% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Greenland Mines and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.